However, these results did not match with those from the pilot study, where circulating levels of CaMK2 were not increased in patients that had suffered an ischemic stroke, and hampers the use of these proteins as potential blood biomarkers of stroke diagnosis. This evidence concerns the gene CAMK2B and Stroke.